Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)

Mathias Rummel(Universitätsklinikum Gießen und Marburg), Richard Greil(Paracelsus Medical University), Christian Buske(University Hospital Ulm), Alexander Burchardt(Johannes Gutenberg University Mainz), Manfred Reeb, Bernd Hertenstein(San Antonio College), Christina Balser(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Georg Maschmeyer(Radboud University Medical Center), Axel Hinke, Michael Koenigsmann, Frank Kauff(Duke University), Elisabeth Lange(Evangelisches Krankenhaus Hamm), Georg Schliesser, Christian Lerchenmüller, Tobias Gaska(Brüderkrankenhaus St. Josef Paderborn), Dirk Behringer(Augusta-Kranken-Anstalt), Juergen Barth, Jan Dürig(Essen University Hospital)
Clinical Lymphoma Myeloma & Leukemia
August 29, 2018
Cited by 6


Related Papers